Pradžia › Ewingo sarkoma › Masčusetsas
Ewingo sarkoma klinikiniai tyrimai Masčusetsas
6 tyrimai dėl Ewingo sarkoma ieško dalyvių vietose Masčusetsas.
Miestai Masčusetsas
Oficialus tyrimo tekstas (anglų kalba)
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 2 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07297979Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103Lurbinectedin in FET-Fused Tumors
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Amžius 10 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-06-02 · NCT07197554Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 49 · Visoms lytims · Atnaujinta 2026-02-19 · NCT06709495Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.